FIVE years later, NEARLY 70% of people in the vaccine group are CANCER-FREE. The vaccine also cut a person’s risk of the cancer metastasizing by NEARLY 60%.
FIVE years later, NEARLY 70% of people in the vaccine group are CANCER-FREE. The vaccine also cut a person’s risk of the cancer metastasizing by NEARLY 60%.
Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational
Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational
@4157.bsky.social exclusively following women. Using a pic of artist Christopher Obetz, whose images are in prolific use by romance scammers, stolen from his verified Instagram account.
scamdigger.com/forum/viewto...
www.instagram.com/christopher_...
@4157.bsky.social exclusively following women. Using a pic of artist Christopher Obetz, whose images are in prolific use by romance scammers, stolen from his verified Instagram account.
scamdigger.com/forum/viewto...
www.instagram.com/christopher_...
Some details on the melanoma breakthrough:
Moderna and Merck announced on August 19, 2026, that their personalized mRNA cancer vaccine, intismeran (V940/mRNA-4157), successfully met its goals in a pivotal Phase 3 trial.
Some details on the melanoma breakthrough:
Moderna and Merck announced on August 19, 2026, that their personalized mRNA cancer vaccine, intismeran (V940/mRNA-4157), successfully met its goals in a pivotal Phase 3 trial.
🔮 ficlet one: 2001 words
🐍 ficlet two: 4157 words
working on ficlet three today... 🦇👀
and there just might be... treats for these fics, as well... 🍬👀
🔮 ficlet one: 2001 words
🐍 ficlet two: 4157 words
working on ficlet three today... 🦇👀
and there just might be... treats for these fics, as well... 🍬👀
https://www.ft.com/content/5342a7e4-4908-4157-8038-1ee00fcd6fa0
https://www.ft.com/content/5342a7e4-4908-4157-8038-1ee00fcd6fa0
Frame: 4157/25156
Frame: 4157/25156
– Personalized melanoma vaccine (mRNA-4157) ↓ recurrence
– Trials ongoing in lung, bladder, colorectal CA
– Transient CAR-T via mRNA (no genome editing)
– Plug-and-play approach for multi-antigen vaccines
– Personalized melanoma vaccine (mRNA-4157) ↓ recurrence
– Trials ongoing in lung, bladder, colorectal CA
– Transient CAR-T via mRNA (no genome editing)
– Plug-and-play approach for multi-antigen vaccines